Abstract:8533 Background: Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residue disease in lung cancer after definitive treatment. Herein, we investigated the value of ctDNA in prognosing risk of relapse and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer (NSCLC) patients. Methods: Forty-one surgical NSCLC patients were enrolled. Tumor tissues were collected at surgery and subjected to targeted NGS of 1021 cancer-related genes. The serial peripheral blood samples were collected at postoperative one month and then at every third or sixth month and subjected to ultra-deep targeted NGS covering 338 genes. Results: From 41 eligible patients including 18 patients with stage I disease, 2 with stage II and 21 with stage III, 41 tumor tissues and 137 plasma samples were enrolled and successfully tested. In tissue samples, 323 somatic variations were identified, with a median of 8 (range, 1-21) gene variations detected in each patient. TP53 was the most common mutation (63.41%), followed by EGFR (58.53%), LRP1B (17.07%) and KRAS (14.63%). The first-postoperative ctDNA positive was found in 13 of 41 patients (31.71%), 9 stage III, 2 stage II and 2 stage I. During a median 9.47 months follow-up, 38.46% (5/13) patients with detectable ctDNA in the first postoperative blood sample experienced recurrence, while 3.57% (1/28) patients with undetectable ctDNA ultimately recurred. The DFS can be stratified by the first-postoperative ctDNA status, with ctDNA-positive groups having significantly reduced DFS (p < 0.05). We detected ctDNA in at least one time point after surgery in 17 patients (41.46%), 5 of them (29.41%) experienced recurrence. Twenty-four patients without ctDNA detection during postoperative surveillance, one (4.17%) of them ultimately recurred. Serial ctDNA detection revealed disease recurrence ahead of radiologic imaging by a median of 5.25 months (range, 0.98-14.19). Among the 41 patients, 6 patients had surgery alone, 35 patients received adjuvant therapy. For these 35 patients, ctDNA analysis can stratify patients before and after adjuvant therapy. Recurrence ratio was 33.33% (4/12) in patients with detectable and 4.34% (1/23) in patients with undetectable ctDNA before adjuvant therapy. For ctDNA analysis after adjuvant therapy, no patients (11/11) with negative ctDNA had disease-recurrence while 33.33% (1/3) patients with positive ctDNA experienced recurrence. All four patients with clearance ctDNA by adjuvant therapy remained disease free. Conclusions: For NSCLC patients, postoperative ctDNA is a prognostic marker, which reveals disease recurrence ahead of radiographic examination. Importantly, ctDNA-detecting may facilitate personalized adjuvant therapy, and applying adjuvant therapy to the patients with detectable ctDNA could bring clinical benefits for them.

Postoperative circulating tumor DNA testing based on tumor naïve strategy after liver metastasis surgery in colorectal cancer patients

Circulating Tumor DNA As a Promising Biomarker of Relapse Risk for Stage II-III Colorectal Cancer.

Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study

Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non–small cell lung cancers.

Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: A prospective cohort study

458P Circulating Tumor DNA Analysis Predicting Recurrence Risk in Patients with Stage I-III Colorectal Cancer

Effect of dynamic circulating tumor DNA minimal residual disease detection on recurrence surveillance and second resection rate after curative intent resection of colorectal liver metastasis: A prospective cohort study.

Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases

Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer

Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer

Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.

Use of circulating tumor DNA analysis to predict recurrence and need for adjuvant chemotherapy in stage I-IV colorectal cancer.

Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis

Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I–IV colorectal cancer

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients

Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases

Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer

Prognostic value of circulating tumor DNA following local therapy in colorectal cancer with liver metastases.

Feasibility of ctDNA in detecting minimal residual disease and predicting recurrence for colorectal cancer liver metastases

Serial Circulating Tumor DNA to Predict Early Recurrence in Patients with Hepatocellular Carcinoma: a Prospective Study.